312 related articles for article (PubMed ID: 9628601)
1. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group.
Nseyo UO; Shumaker B; Klein EA; Sutherland K
J Urol; 1998 Jul; 160(1):39-44. PubMed ID: 9628601
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium.
Manyak MJ; Ogan K
J Endourol; 2003 Oct; 17(8):633-9. PubMed ID: 14622483
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience.
Nseyo UO; DeHaven J; Dougherty TJ; Potter WR; Merrill DL; Lundahl SL; Lamm DL
J Clin Laser Med Surg; 1998 Feb; 16(1):61-8. PubMed ID: 9728133
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
5. [Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?].
Kriegmair M; Waidelich R; Baumgartner R; Lumper W; Ehsan A; Hofstetter A
Urologe A; 1994 Jul; 33(4):276-80. PubMed ID: 7941172
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
[TBL] [Abstract][Full Text] [Related]
7. Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer.
Lee LS; Thong PS; Olivo M; Chin WW; Ramaswamy B; Kho KW; Lim PL; Lau WK
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):213-20. PubMed ID: 21112542
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy in the management of bladder cancer.
Nseyo UO
J Clin Laser Med Surg; 1996 Oct; 14(5):271-80. PubMed ID: 9612193
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy.
Nseyo UO
Urol Clin North Am; 1992 Aug; 19(3):591-9. PubMed ID: 1386168
[TBL] [Abstract][Full Text] [Related]
10. Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers.
Xiao Z; Brown K; Tulip J; Moore RB
J Urol; 2003 Jan; 169(1):352-6. PubMed ID: 12478188
[TBL] [Abstract][Full Text] [Related]
11. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder.
Walther MM; Delaney TF; Smith PD; Friauf WS; Thomas GF; Shawker TH; Vargas MP; Choyke PL; Linehan WM; Abraham EH; Okunieff PG; Glatstein E
Urology; 1997 Aug; 50(2):199-206. PubMed ID: 9255289
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer.
Waidelich R; Stepp H; Baumgartner R; Weninger E; Hofstetter A; Kriegmair M
J Urol; 2001 Jun; 165(6 Pt 1):1904-7. PubMed ID: 11371878
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
McKiernan JM; Holder DD; Ghandour RA; Barlow LJ; Ahn JJ; Kates M; Badalato GM; Roychoudhury A; Decastro GJ; Benson MC
J Urol; 2014 Dec; 192(6):1633-8. PubMed ID: 24996128
[TBL] [Abstract][Full Text] [Related]
15. Superficial bladder cancer therapy.
Schenkman E; Lamm DL
ScientificWorldJournal; 2004 Jun; 4 Suppl 1():387-99. PubMed ID: 15349563
[TBL] [Abstract][Full Text] [Related]
16. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
18. Integral photodynamic therapy of superficial bladder tumors with special reference to carcinoma in situ.
Hisazumi H; Naito K; Uchibayashi T; Hirata A; Komatsu K
Scand J Urol Nephrol Suppl; 1991; 138():161-5. PubMed ID: 1785000
[TBL] [Abstract][Full Text] [Related]
19. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
20. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
Griffiths TR; Charlton M; Neal DE; Powell PH
J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
